FATIMA RASOOL

Dr. FATIMA RASOOL

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 September 2022 in Molecules
Verified
Journal Article
Open access
PDF file
MYMuhammad yousuf
Muhammad yousuf
HKHAJI MUHAMMAD SHOAIB KHAN
HAJI MUHAMMAD SHOAIB KHAN
FRFATIMA RASOOL
FATIMA RASOOL
KKKashif ur Rehman Khan
Kashif ur Rehman Khan
FUFaisal Usman
Faisal Usman
CCCarlos Adam Conte-Junior
Carlos Adam Conte-Junior
Emulgel is a new innovatory technique for drug development permitting controlled release of active ingredients for topical administration. We report a stable emulgel of 4% Piper nigrum extract (PNE) prepared using 80% ethanol. The PNE-loaded formulation had an antioxidant activity of 84% and tyrosinase inhibition was 82%. Prepared formulation rendered spherical-shaped globules with high zeta potential (−45.5 mV) indicative of a stable system. Total phenolic contents were 58.01 mg GAE/g of dry extract whereas total flavonoid content was 52.63 mg QE/g of dry extract. Sun protection factor for PNE-loaded emulgel was 7.512 and formulation was stable without any evidence of physical and chemical changes following 90 days of storage. Gas chromatography-mass spectroscopy (GC-MS) revealed seventeen bioactive compounds in the PNE including monoterpenoids, triterpenoids, a tertiary alcohol, fatty acid esters, and phytosterols. In silico studies of GC-MS identified compounds show higher binding affinity in comparison to standard kojic acid indicating tyrosinase inhibition. It can be concluded that PNE-loaded emulgel had prominent antioxidant and tyrosinase inhibition and can be utilized as a promising topical system for anti-aging skin formulation.
1

23 August 2023 in Heliyon
Verified
Journal Article
Open access
HKHAJI MUHAMMAD SHOAIB KHAN
HAJI MUHAMMAD SHOAIB KHAN
NTNishma Tanveer
Nishma Tanveer
TATahreem Arshad
Tahreem Arshad
FRFATIMA RASOOL
FATIMA RASOOL
MUMohammad N. Uddin
Mohammad N. Uddin
Mohsin kaziMohsin kazi
Mohsin kazi
Alpha arbutin is a skin-whitening agent in cosmetics. Structurally, it is 4-hydroxyphenyl-α-glucopyranoside. Ethosomes encourage the formation of lamellar-shaped vesicles with improved solubility and entrapment of whitening agents. The objective of this study was to fabricate an optimized nanostructured ethosomal gel loaded with alpha arbutin for the treatment of skin pigmentation.

9 August 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
RTRabia Tasneem
Rabia Tasneem
HKHAJI MUHAMMAD SHOAIB KHAN
HAJI MUHAMMAD SHOAIB KHAN
FRFATIMA RASOOL
FATIMA RASOOL
KKKashif ur Rehman Khan
Kashif ur Rehman Khan
Umair MuhammadUmair Muhammad
Umair Muhammad
Sameh A. KormaSameh A. Korma
Sameh A. Korma
Antioxidants from natural sources are extensively attaining consideration to avert the skin from damage and aging caused by free radicals. Flaxseed (Linum usitatissimum L.), a natural therapeutic agent, was meant to be explored cosmeceutical by quantifying its potential phytoconstituents and to be incorporated into a microemulgel for topical use. Hydroalcoholic fractions (both methanolic and ethanolic; 80%) flaxseed extracts were subjected to phytochemical screening by quantifying total phenolic content (TPC), total flavonoid content (TFC), and high-performance liquid chromatography-ultraviolet (HPLC-UV), and for biological activities through 2,2-diphenyl-1-picrylhydrazyl (DPPH) assay, tyrosinase inhibition assay, and sun protection factor (SPF). Ethanolic fraction was selected for further study by TPC (18.75 mg gallic acid equivalent/g) and TFC (1.34 mg quercetin equivalent/g). HPLC-UV analysis showed the existence of benzoic, quercetin, caffeic, vanillic, p-coumaric, gallic, cinnamic, syringic, and sinapic acids. Biological activities showed 87.00%, 72.00%, and 21.75 values for DPPH assay, tyrosinase inhibition, and SPF assays, respectively. An oil-in-water (OW) microemulsion containing the flaxseed extract, with 99.20 nm Zeta size, −19.3 Zeta potential and 0.434 polydispersity index was developed and incorporated in Carbopol-940 gel matrix to formulate an active microemulgel with 59.15% release in in vitro studies. The successfully formulated stable active microemulgel produced statistically significant effects (p < 0.05), in comparison to a placebo, on skin erythema, melanin, sebum, moisture, and elasticity, in a noninvasive in vivo study performed on 13 healthy human female volunteers. Other cosmeceutical products can also be formulated from flaxseed, making it a considerable candidate for further utilization in the pharmaceutical industry.

1 June 2020 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
AKAsad Majeed Khan
Asad Majeed Khan
MHMuhammad Hanif
Muhammad Hanif
NBNadeem Irfan Bukhari
Nadeem Irfan Bukhari
RSRahat Shamim
Rahat Shamim
FRFATIMA RASOOL
FATIMA RASOOL
SSSana Shafique
Sana Shafique
Background: Severe bleeding and perforation of the colon and rectum are complications of ulcerative colitis which can be treated by a targeted drug delivery system. Purpose: Development of colon-targeted delivery usually involves a complex formulation process and coating steps of pH-sensitive methacrylic acid based Eudragit®. The current work was purposefully designed to develop dicalcium phosphate (DCP) facilitated with Eudragit-S100-based pH-dependent, uncoated mesalamine matrix tablets. Materials and Methods: Mesalamine formulations were compressed using wet granulation technique with varying compositions of dicalcium phosphate (DCP) and Eudragit-S100. The developed formulations were characterized for physicochemical and drug release profiles. Infrared studies were carried out to ensure that there was no interaction between active ingredients and excipients. Artificial neural network (ANN) was used for the optimization of final DCP-Eudragit-S100 complex and the experimental data were employed to train a multi-layer perception (MLP) using quick propagation (QP) training algorithm until a satisfactory root mean square error (RMSE) was reached. The ANN-aided optimized formulation was compared with commercially available Masacol®. Results: Compressed tablets met the desirability criteria in terms of thickness, hardness, weight variation, friability, and content uniformity, ie, 5.34 mm, 7.7 kg/cm2, 585± 5 mg (%), 0.44%, and 103%, respectively. In-vitro dissolution study of commercially available mesalamine and optimized formulation was carried out and the former showed 100% release at 6 h while the latter released only 12.09% after 2 h and 72.96% after 12 h which was fitted to Weibull release model with b value of 1.3, indicating a complex release mechanism. Conclusion: DCP-Eudragit-S100 blend was found explicative for mesalamine release without coating in gastric and colonic regions. This combination may provide a better control of ulcerative colitis.

1 January 2012 in Research in Complementary Medicine
Verified
Journal Article
Closed access
NANaveed Akhtar
Naveed Akhtar
AKAli B. Khan
Ali B. Khan
SMSaid Muhammad
Said Muhammad
MAMahmood Ahmed
Mahmood Ahmed
HKHaji M. Shoaib Khan
Haji M. Shoaib Khan
TSTariq Saeed
Tariq Saeed
This study aimed to formulate a water-in-oil emulsion (formulation) of Terminalia chebula versus its vehicle (base) as control, and investigate its effects on skin melanin, skin erythema, skin moisture content, and transepidermal water loss (TEWL). Base containing no active material, and formulation containing 5% concentrated extract of T. chebula, were developed. Different stability parameters were monitored at 8, 25, and 40 °C, as well as 40 °C + 75% relative humidity, for a period of 4 weeks. It was concluded that the creams remained stable at all storage conditions. Both base and formulation were applied to the cheeks of human volunteers for a period of 8 weeks. Different skin parameters were monitored every week to measure any effect produced by these creams. Changes in TEWL produced by base and formulation were insignificant (p > 0.05) with respect to time while significant (p ≤ 0.05) with respect to base and formulation. The skin moisture content increased after the application of formulation throughout the study period; this effect was insignificant (p > 0.05) with respect to time while significant (p ≤ 0.05) with respect to base and formulation. Both base and formulation showed insignificant (p > 0.05) effects on skin melanin content with respect to time. Skin erythema was reduced by the formulation. Both base and formulation produced statistically insignificant (p > 0.05) effects on skin sebum. Both creams were aesthetic with respect to sensory evaluation. T. chebula topical cream showed a positive rejuvenating effect on human skin. Hopefully, this study will encourage more attention towards the research and utilization of herbal medicines.

21 October 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
FRFATIMA RASOOL
FATIMA RASOOL
ANAyesha Naseem
Ayesha Naseem
HJHuma Javaid
Huma Javaid
ZAZobia Afzal
Zobia Afzal
Celecoxib (CLX), a selective COX-2 inhibitor and BCS Class II drug, is widely used for osteoarthritis and rheumatoid arthritis but having poor aqueous solubility (4.2 µg/mL) and limited dissolution, restricting its oral bioavailability. This study aimed to enhance CLX solubility and dissolution using integrated computational and experimental approaches. Simulated crystal morphology revealed a dominant (1 0 0) face, indicating a plate-like crystal habit that may hinder dissolution. Molecular dynamics simulations further identified hydroxypropyl β-cyclodextrin (HP-βCD) as the most compatible polymer, exhibiting the lowest interaction parameter (χ = − 5.86) and mixing energy (Emix = − 3.47 kcal/mol). Physical mixtures (PM1–PM4) were prepared at a 1:1 drug-to-polymer ratio and evaluated for solubility and recrystallization inhibition. PM1 (CLX–HP-βCD) showed the highest solubility (64.18 µg/mL) and longest induction time (140 s), indicating improved supersaturation stability. Lyophilized solid dispersions (SD1–SD4) were then developed and characterized using solubility studies, FTIR spectroscopy, microscopy, and in vitro dissolution testing. SD1 exhibited the greatest solubility enhancement (645 µg/mL), over 150-fold higher than pure CLX. FTIR and microscopy confirmed molecular dispersion and amorphization within the hydrophilic matrix. In vitro dissolution testing showed SD1 achieved 78.5% drug release in 3 h, with release kinetics best described by first-order (R2 = 0.9661) and Korsmeyer–Peppas (n = 0.879) models. These dispersions were compressed into tablets (T1–T4) and assessed for mechanical properties and drug release. T1 demonstrated the highest release (99.88% in 3 h), with release kinetics fitting first-order (R2 = 0.8996) and Hixson–Crowell (R2 = 0.9351) models. Overall, HP-βCD-based lyophilized solid dispersion emerged as a highly effective system for enhancing the solubility, dissolution, and ultimately the oral bioavailability of celecoxib.